Therapeutic efficacy of sintilimab combined with anti-vascular drugs in treatment of patients with advanced liver cancer receiving TACE
Objective To investigate the efficacy and safety of sintilimab combined with sorafenib+transcatheter arterial chemoembolization(TACE)in the treatment of stage Ⅲ hepatocellular carcinoma.Methods Seventy-nine patients with unresectable advanced primary hepatocellular carcinoma admitted to Shaoxing Shangyu People's Hospital from January 2018 to September 2022 were enrolled in this study and divided into study group(n=38,sintilimab+sorafenib+TACE regimen)and the control group(n=41,sorafenib+TACE regimen)according to the treatment method.Then the disease control rate(DCR),objective remission rate(ORR),overall survival(OS),progression-free survival(PFS)and adverse reactions were compared between the two groups.Results The ORR and DCR in the study group were higher than those in the control group at postoperative 1 month(60.53%vs 34.15%,χ2=5.512,P=0.019).At 18 months of follow-up,the survival rate of the study group was 78.95%(30/38)while that of the control group was 63.41%(26/41).There was no statistically significant difference in the overall survival rate between the two groups(P>0.05).The median PFS and OS of the study group were 12.0 months and 14.9 months,respectively,which were higher than those of the control group at 7.3 months and 10.9 months(long rank χ2=4.075,4.380,P=0.044,0.036).There was no statistically significant difference in the probability of grade 3 adverse reactions such as gastrointestinal reactions(2.6%vs 4.9%),rash(2.6%vs 0%)and hypertension(13.2%vs 4.9%)between the study group and the control group(all P>0.05).Conclusion The combination of sintilimab and Sorafenib+TACE in the treatment of advanced liver cancer can effectively improve the objective remission rate,prolong the survival time of patients and does not significantly increase the incidence of serious adverse reactions,demonstrating good safety and efficacy.
NETL
NSTL
万方数据
